Oncobiologics (NASDAQ:OTLK) Releases Earnings ResultsMarket Beat·2 days ago, 07:11 PMOTLK-14.90%GS-0.31%
Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9PUBT·2 days ago, 06:40 PMOTLK-14.90%
Outlook Therapeutics (OTLK) Fiscal Q3 2026 Earnings Call: LYTENAVA Launch and Revenue GuidanceTradingKey·2 days ago, 03:04 PMOTLK-14.90%
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Callbenzinga_article·2 days ago, 08:25 AMOTLK-14.90%
OTLK: FDA approval and launch plans for LYTENAVA drive growth prospects amid improved financialsQuartr·2 days ago, 06:41 AMOTLK-14.90%
Outlook Therapeutics FY26 Q3 net loss narrows to $20.32 million; revenue drops to $9,000PUBT·2 days ago, 06:15 AMOTLK-14.90%
Options Volatility and Implied Earnings Moves Today, August 14, 2026Tip Ranks·2 days ago, 06:05 AMOTLK-14.90%DGXX-3.87%
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analystsbenzinga_article·Aug 14 at 12:30 AMOTLK-14.90%
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ | OTLK Stock NewsStockTitan·Aug 13 at 10:15 PMOTLK-14.90%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Aug 13 at 12:05 PMBYSI-15.78%OMER-0.92%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Aug 13 at 07:05 AMABEO-5.67%NRC-0.56%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Aug 12 at 04:06 PMVBIO+11.59%OTLK-14.90%
Outlook Therapeutics launches public offering with accompanying stock purchase warrantsPUBT·Aug 12 at 03:01 PMOTLK-14.90%
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants | OTLK Stock NewsStockTitan·Aug 12 at 12:45 PMOTLK-14.90%
